How to Evaluate Protocol Feasibility Before Committing to a Study

Most sites review the feasibility questionnaire closely and skim the protocol itself. That is backward. The questionnaire is where you tell the sponsor what you can do. The protocol is where you find out whether it is actually true. A stack of criteria that reads fine in the synopsis can still eliminate most of your patient population, and you will not see it until you count.

Protocol feasibility is not the same as site feasibility

Site feasibility asks a general question: is this site capable of running trials well? Staff, infrastructure, IRB relationship, regulatory history. A broader feasibility assessment covers that ground.

Protocol feasibility asks a narrower, sharper question: can this specific site run this specific protocol, against its current patient population, right now? A site with excellent infrastructure and a strong PI can still be the wrong fit for one particular study, because the answer depends on the document, not the site's general reputation.

A site can pass every general capability check and still be wrong for a specific protocol. That is the gap this review closes.

Start with the eligibility criteria, not the synopsis

The protocol synopsis is written to sell the study. The eligibility section is written to run it. Read the full inclusion and exclusion list, not the summary paragraph, and count the individual criteria rather than treating them as one block.

Each additional criterion multiplies against the ones before it. A protocol requiring a recent hypoglycemic event within a narrow window, continuous glucose monitor use for at least three months, and a specific insulin delivery method is not asking for three easy filters. It is asking for the intersection of all three, which can shrink an apparently large eligible pool to a handful of real candidates. The same pattern shows up in respiratory protocols that require a documented exacerbation history plus prior treatment with a specific drug class: each line looks reasonable alone and brutal in combination.

Multiply the survival probability of each criterion against your population. Do not add them up. The math is unforgiving, and it is the first place a protocol tells you the truth about your fit.

Map the visit schedule and procedure burden before you agree to it

Eligibility decides who can enroll. Visit burden decides who stays enrolled. Pull the schedule of events out of the protocol and count real numbers: total visits, washout periods, imaging or blood draw frequency, and any device or storage requirement your site does not already run routinely.

An intranasal biologic with cold-chain storage requirements, a device that needs a dedicated training session, or a visit cadence that assumes a working-age patient can take four weekday afternoons off, each of these is a burden that shows up nowhere in the eligibility criteria but drives your actual retention and staff workload.

A protocol that reads fine on paper can still be more than your patients or your coordinators will tolerate. Map the burden before you sign, not after the first missed visit.

Run the screening math before you commit to a number

Once you know the real eligibility bar and the real burden, build your own enrollment estimate. Start with patients per year who have the condition, apply the compounded eligibility yield from the criteria review, then apply your historical screen-to-consent rate for comparable protocols. What is left is a defensible projection over the actual enrollment window, not the number the protocol's synopsis assumes every site will hit.

Sites that skip this step and commit to the sponsor's target number are the same sites that later show up in the enrollment shortfall conversation. The number has to come from your data, or it is a guess with a decimal point.

Check operational fit against what the protocol actually requires

Eligibility and burden tell you whether the study fits your patients. Operational fit tells you whether it fits your site. Walk through what the protocol requires against what you actually have: specialized equipment, drug storage and handling, IRB turnaround for this sponsor, and whether your coordinators have bandwidth once current studies are accounted for.

Pay particular attention to competing trials already running at your site. A protocol with narrow eligibility criteria that overlap heavily with a study you are already running does not add a new patient pool. It splits the one you have.

Discover an equipment or staffing gap during the review, not after the contract is signed. That is the entire point of doing this before you commit.

Red flags that should slow you down

Some signals in a protocol are worth a harder look before you move forward.

A shaky protocol is usually a preview of a shaky trial. The review that catches it now is cheaper than the one that catches it three months in.

A quick go/no-go framework

Once the review is done, four questions decide whether to move forward.

Narrow-eligibility protocols are not automatically a reason to decline. They are a reason to run the numbers first. Sites that do this well can still deliver strongly against a restrictive protocol.

What a protocol-level review protects you from

The sites that skip this step tend to make the same mistake twice: they commit to a protocol based on the synopsis, discover the real eligibility bar three weeks into screening, and then spend the rest of the trial explaining a shortfall that was visible on day one to anyone who read the full criteria list.

The sites that build this review into their process compound something more valuable than any single study: a track record of projections that hold up. Clinical Enroll has delivered randomization across 30+ indications, and the pattern behind those results starts the same way every time, with a protocol reviewed line by line before anyone commits to a number.